Amy Wang, PhD, MBA, is the Chief Executive Officer of Enspire Bio. Her role is to work with the UCLA collaborators and scientific founders to ensure each project moves toward translational development to be clinically relevant. As an entrepreneur and merchant banker, Dr. Wang is focused on life science technologies and therapeutics. Dr. Wang is a co-founder of Pulse Bioscience (NASDAQ: PLSE) and Cue Biopharma (NASDAQ: CUE). She also served as a Board Member and early investor in cell-free liquid biopsy company Liquid Genomics (acquired by NantCell). Prior to her investment banking role, Dr. Wang began her career 15 years ago as a scientist at type 1 diabetes company Amcyte, Inc. (acquired by ReNeuron) and Life Technologies (acquired by ThermoFisher Scientific). Dr. Wang received her B.S. in the Department of Chemistry and Biochemistry and Ph.D. in Biological Chemistry at University of California, Los Angeles and holds an MBA from UCLA Anderson School of Management.
Orian Shirihai, MD, PhD is the Chief Scientific Officer of Enspire Bio. He is the director of the Metabolism Unified Research Theme at the David Geffen School of Medicine at UCLA and Professor of Medicine (Endocrinology) and Molecular & Medical Pharmacology at UCLA. Dr. Shirihai works closely with Enspire Bio’s management and Board to coordinate with the scientific team leaders on each project in the company’s pipeline. Prior to joining UCLA, Dr. Shirihai was with The Department of Medicine at Boston University Medical Center (BUMC) and Boston University School of Medicine. Dr. Shirihai joined BUMC from the Department of Pharmacology at Tufts University, Boston where he was an Adjunct Associate professor. Dr. Shirihai did postdoctoral work with Prof. Stuart Orkin at Harvard University. At BUMC, his lab played a pivotal role in the development of cutting edge technology for high throughput respirometry in collaboration with Seahorse Bioscience (acquired by Agilent Technologies). Dr. Shirihai is a member and founder of the Mitochondria ARC (Advancing Research through Collaborations) which is part of the ARC system of BUMC department of medicine. Dr. Shirihai earned his MD and PhD degrees from the Faculty of Medicine at the Technion Israel Institute of Technology.